Studying QL1706 with chemotherapy for SMARCA4-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage IIIB or IV lung cancer that cannot be removed with surgery or treated with radiation.
- Your tumor has a specific genetic change called SMARCA4 deficiency (loss of the BRG1 protein).
- You have not had previous systemic treatment for advanced lung cancer.
- You are able to take care of yourself (ECOG status 0 or 1) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (anlotinib) with chemotherapy for people with a specific type of lung cancer that has a genetic change called SMARCA4 deficiency. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of two new drugs (QLS31905 and/or QL1706) with chemotherapy for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
Hear when a new SMARCA4-Deficient Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.